Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
A phase 3 trial of Alpelisib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. is a phase 3 interventional study registered as NCT05038735 by Novartis Pharmaceuticals, with 210 participants enrolled, started 2021-12-17 and due to reach its primary completion in 2027-01-28. Interventions recorded: Alpelisib, Fulvestrant and Alpelisib-matching placebo.
Similar pages
not linked directly; found by shared links- TrialStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Shares Alpelisib, Advanced Accelerator Applications (Novartis), Fulvestrant and the tag pipeline.
- TrialStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Shares Alpelisib, Advanced Accelerator Applications (Novartis), Fulvestrant and the tag pipeline.
- TrialClinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), Fulvestrant and the tag pipeline.
- TrialAlpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Shares Alpelisib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Shares Alpelisib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Shares Alpelisib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialComparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.